Six teams have been accepted onto Phase II of the Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation. Selected from the 25 teams that took part in Phase I, three of the Phase II project teams will… Read More
DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More
Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR: … Read More
Closed Loop Medicine has joined the NVIDIA Inception accelerator programme, designed to nurture start-ups and early-stage companies revolutionising industries with technological advancements. The programme supports all stages of a start-up’s life cycle, providing access to the latest tools, expertise, and a network of venture capitalist investors,… Read More
Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures,… Read More
A new accelerator programme at Alderley Park has been launched to support innovation and growth in the region. Bruntwood SciTech’s Life Science Accelerator programme has been designed to cater to the unique needs of early-stage life science companies from across the UK, offering comprehensive support and… Read More
Oxford University spin-out Infinitopes Precision Immunomics has completed a £12.8 ($16) million seed funding round led by Octopus Ventures. The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory,… Read More
Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More
Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More
The Birmingham Drug Discovery Hub (BDDH) has been set up to help University of Birmingham researchers to overcome the ‘valley of death’, where projects fail due to the funding gap between original research and commercial investment. The hub has attracted more than £4 ($4.9) million in… Read More
Bios Health Group has launched the Bios Innovation Circle – a new venture studio and strategic hub, designed to support biotechnology and life science companies towards growing success. The Bios Innovation Circle is a venture studio and strategic hub designed to catalyse the growth of start-ups,… Read More
Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly… Read More
A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The approach to achieve this involves delivering an engineered small artificial (smart)RNA into the cell, where it assembles with endogenous protein co-factors… Read More
DDW Editor Reece Armstrong speaks to Michael Krogh Jensen, Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. RA: How has being part of the Bio Studio programme helped you develop your pipeline?… Read More
A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit is aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein… Read More
Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The phage lysin-based platform – using artificial intelligence (AI) – has attracted a significant €4 million investment from Boehringer Ingelheim Venture… Read More
